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Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal
peripheral neuropathies inherited in an autosomal dominant fashion. Our previous genetic and physical mapping
efforts localized the responsible gene(s) to a well-defined region on human chromosome 7p. Here, we report the
identification of four disease-associated missense mutations in the glycyl tRNA synthetase gene in families with
CMT2D and dSMA-V. This is the first example of an aminoacyl tRNA synthetase being implicated in a human
genetic disease, which makes genes that encode these enzymes relevant candidates for other inherited neuropathies
and motor neuron diseases.
Charcot-Marie-Tooth (CMT) disease constitutes a hetero-
geneous group of peripheral neuropathies estimated to
affect 1 in 2,500 individuals (Skre 1974). The clinical fea-
tures of CMT include muscular weakness and atrophy
in the distal extremities, steppage gait, pes cavus, absent
or diminished deep-tendon reflexes, and impaired sen-
sation (Murakami et al. 1996). Through the measure-
ment of motor nerve conductance velocities (MNCVs),
CMT can be subdivided into two classes (Dyck and Lam-
bert 1968). In CMT1, patients exhibit decreasedMNCVs
with demyelinating axons. In CMT2, patients exhibit
normal MNCVs and no demyelination but have de-
creased amplitudes of evoked motor and sensory nerve
responses. To date, six subtypes of CMT2 have been
reported (CMT2A–F), with the genes responsible for
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three of these now identified: (1) CMT2A: kinesin su-
perfamily gene (KIF1B) (Zhao et al. 2001); (2) CMT2B:
RAS-related GTP-binding protein 7 gene (RAB7) (Ver-
hoeven et al. 2003); and (3) CMT2E: neurofilament light
chain gene (NEFL) (Mersiyanova et al. 2000).
CMT2D (MIM 601472) was first mapped to chromo-
some 7p in a large North American family exhibiting a
peripheral neuropathy that was more pronounced in the
upper extremities (family 1 in table 1) (Ionasescu et al.
1996). Subsequently, an additional North American fam-
ily was identified with a CMT2 phenotype that mapped
to 7p (family 2 in table 1) (Pericak-Vance et al. 1997).
The CMT2D region overlaps an interval shown else-
where to contain a locus for distal spinal muscular at-
rophy type V (dSMA-V) mapped in a Bulgarian kindred
(family 3 in table 1) (Christodoulou et al. 1995). dSMA-
V is a neuromuscular disorder with a phenotype similar
to CMT2D; both diseases are associated with a more
severe phenotype in the upper extremities that generally
affects the thenar eminence and first dorsal interosseous
muscle groups. The main characteristic that distinguishes
these disorders is a distal sensory loss in patients with
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Table 1
Families with CMT2D and dSMA-V Analyzed in This Study
Family Classification
Age at Onset
(years)
Symptoms More
Severe in
Upper Extremities
Symptoms Prominent in
Thenar Eminence
and First Dorsal Interosseous References
1 CMT2 16–30a  ND Ionasescu et al. 1996
2 CMT2 ND ND ND Pericak-Vance et al. 1997
3 dSMA 17b   Christodoulou et al. 1995
4 CMT2/dSMA 18b   Sambuughin et al. 1998
5 dSMA ND   The present study (see fig. 3D)
NOTE.— p finding present; ND p not determined.
a Range in age at onset.
b Median age at onset.
CMT2D. Genetic mapping of aMongolian kindred (fam-
ily 4 in table 1), with phenotypic features of bothCMT2D
and dSMA-V, implicated the same region on chromo-
some 7p, thereby raising the likely possibility that the
two diseases are allelic (Sambuughin et al. 1998). In
addition, we recently identified an Algerian Sephardic
Jewish family presenting with a dSMA phenotype (fam-
ily 5 in table 1). Affected members are present inmultiple
generations, and the pattern of inheritance is consistent
with an autosomal dominant trait. A 53-year-old man
and his 27-year-old daughter presented with symptoms
of bilateral hand amyotrophy. Hand weakness began at
ages 13 and 26 years, respectively, and physical exam-
ination revealed decreased muscle strength limited to
thenar and dorsal interosseous muscles of both hands.
Strength was deemed normal in all other muscles in both
patients. Tendon reflexes were normal, and physical
exam revealed no sensory impairment. Electromyography
showed a pure motor neuropathy limited to the hands,
with preserved conduction velocities; sensory conduction
studies were normal. On the basis of these studies, we
classified this family as having dSMA type V.
Our previous studies indicated that the CMT2D/
dSMA-V critical region encompasses an ∼1.25-Mb re-
gion on chromosome 7p14 (Ellsworth et al. 1999). To
refine this interval, additional genotyping was performed
on families 1, 2, and 4. We identified a single recom-
bination event at marker 7p-3180 (a novel dinucleotide
repeat at chr7:29490559–29490683 of the November
2002 build on the UCSC Genome Browser) in the un-
affected offspring of an affected individual from family
4 (data not shown). This finding narrows the CMT2D/
dSMA-V critical region to ∼980 kb between markers
7p-3180 (telomeric) andD7S632 (centromeric) (fig. 1A).
Of note, families 1 and 2 bear the same haplotype across
this region, raising the possibility that they carry the same
CMT2D allele (data not shown).
Analysis of the CMT2D/dSMA-V critical region re-
veals the presence of 11 known genes (fig. 1A). These
genes were analyzed for mutations by sequencing PCR-
amplified exons generated from representative members
of each family. Screening of the glycyl tRNA synthetase
gene (GARS [MIM 600287]) revealed mutations in all
five families (fig. 2A). Specifically, the following four het-
erozygous missense mutations were detected: (1) in fami-
lies 1 and 2, a 1236grc variant that results in a predicted
G240R amino acid change (note that this is consistent
with the above haplotype data for these two families); (2)
in family 3, a 904crt variant that results in a predicted
L129P amino acid change; (3) in family 4, a 730arg
variant that results in a predicted E71G amino acid
change; and (4) in family 5, a 2094grc nucleotide change
that results in a predicted G526R amino acid change.
Analysis of available individuals from each pedigree
revealed that the mutations consistently segregate with
the disease, with representative examples shown in figure
3A, 3C, and 3D. We also tested human-rodent hybrid
cell lines derived from family 1, one carrying the “af-
fected” (i.e., CMT2D-associated) chromosome 7 haplo-
type and one carrying an “unaffected” chromosome 7
haplotype. Sequence analysis revealed that the G240R
mutation resides only on the copy of chromosome 7 bear-
ing the affected haplotype (fig. 3B).
To rule out the possibility that the above sequence
variants represent rare polymorphisms, we genotyped
appropriate control populations by PCR amplification
and DNA sequencing or RFLP analysis. None of these
mutations were encountered in the GARS gene of any
control sample. For all mutations, screening was per-
formedwith amixed-ethnic population collected inNorth
America (described in Struewing et al. [1995]); for the
mutations found in the Mongolian, Bulgarian, and Se-
phardic Jewish families, additional screening was per-
formed with suitably matched controls. Our results re-
vealed that: (1) E71G was absent in 398 unrelated
chromosomes (130 from a Mongolian population and
268 from the mixed-ethnic population); (2) L129P was
absent in 376 unrelated chromosomes (200 from an
Eastern European population and 176 from the mixed-
ethnic population); (3) G240R was absent in 368 un-
related chromosomes from the mixed-ethnic population;
and (4) G526R was absent in 360 unrelated chromo-
somes (160 from a Sephardic Jewish population and 200
from the mixed-ethnic population).
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Figure 1 Localization, organization, and expression of the GARS gene. A, The interval of human chromosome 7p14 harboring the
CMT2D/dSMA-V gene(s) is defined by genetic markers 7p-3180 and D7S632, spans ∼980 kb, and contains the indicated 11 known genes (all
with corresponding GenBank records). B, The GARS gene spans ∼40 kb and contains 17 exons. C, Northern analysis reveals that the ∼2.7-
kb GARS transcript is ubiquitously expressed, with notable positive expression in the brain and spinal cord (arrows).
The human GARS protein is encoded by a 17-exon
gene that spans ∼40 kb on chromosome 7p14 (fig. 1B)
and that is expressed in a ubiquitous fashion (fig. 1C),
including the brain and spinal cord (tissues relevant for
neurodegenerative diseases). Examination of the four
CMT2D/dSMA-V–associated mutations reveals striking
conservation of the altered amino acids. Specifically, in
all but one case, the variant amino acid is identical in
organisms distributed across wide taxonomic spans, from
primates to yeast (fig. 2C; see the “Electronic-Database
Information” section for GenBank accession numbers for
multispecies amino acid sequences). The one exception
is the human residue G240 (a glycine). In roundworm,
there is an alanine at this position (albeit these two amino
acids are quite similar in terms of side chain size and
charge).
The above genetic data implicate mutations in the
GARS gene as the cause of the neurodegenerative dis-
orders, CMT2D and dSMA-V. GARS is a member of
the family of aminoacyl tRNA synthetases responsible
for charging tRNAs with their cognate amino acids. The
functional holoenzyme exists as a homodimer (reviewed
in Freist et al. [1996]) and contains three major func-
tional domains (fig. 2B): (1) the WHEP-TRS domain
(residues 13–63; pfam00458 in the NCBI Conserved
Domain Database) for conjugation with other amino-
acyl tRNA synthetases in enzyme complexes; (2) the core
catalytic domain (residues 92–168 and 241–324; pfam
00587) for ligation; and (3) the anticodon-binding do-
main (residues 557–655; pfam03129) for recognition of
glycine-specific tRNAs. One of the identified mutations
(L129P) falls within the catalytic core (fig. 2B), whereas
another (G240R) lies one residue upstream of the cat-
alytic core (fig. 2B) and two residues upstream of a
highly conserved LRPETAQ sequence. This stretch of
amino acids is fully conserved between human andTher-
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Figure 2 Characterization, localization, and conservation of GARS mutations. A, Representative sections of sequence chromatograms
are shown for the regions encompassing the identified GARS mutations in the indicated families. Arrows denote each mutation (present in a
heterozygous state), with the resulting amino acid changes depicted below along with an indication of their relative positions in the GARS
protein. B, The known functional domains of the GARS protein are indicated in green (WHEP-TRS enzyme conjugation domain), red (core
catalytic domain), and yellow (Gly-tRNA anticodon binding domain). C, For each of the four detected mutations, the variant amino acid is
shown along with the flanking GARS sequence in multiple, evolutionarily diverse species. Note that each specific amino acid change is given
at the top, with the relevant position depicted in red for the sequence in each species. Dashes indicate where sequence data were unavailable.
mus thermophilus; in the latter species, it composes a
loop and helix structure essential for forming the glycine-
binding pocket (reviewed in Freist et al. [1996]). The
positions of these two mutations in conjunction with the
presence of mutations across the GARS protein suggest
a corresponding loss or decrease in enzyme activity. It
is possible that these missense mutations act in a domi-
nant negative fashion, such that the presence of a mutant
subunit within dimers (i.e., mutant/wild type, mutant/
mutant) greatly reduces overall GARS activity.
To investigate further the possible functional impact
of these mutations, we attempted to model the affected
amino acids on three-dimensional structures available for
the T. thermophilus GARS protein. Human GARS ex-
hibits high overall similarity to these structures; however,
the absolute identity between the human and T. thermo-
philus GARS is only 27%–29% (A. Baxevanis, personal
communication). Although some of the identified muta-
tions fall within structured regions, standard threading
techniques (e.g., Bryant and Lawrence 1993) to examine
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Figure 3 Segregation of GARS mutations with CMT2D/dSMA-V. A, Representative branch of family 1, showing segregation of the
G240R mutation (amino acid change shown in red) with CMT2D. B, Sequence analysis of the G240R mutation in separated affected and
unaffected copies of human chromosome 7 from family 1 (see text). Note that the 2094c allele (arrow) is present only on the affected chromosome
(lower panel). C, Representative branch of family 4 showing segregation of the E71G mutation (amino acid change shown in red) with CMT2D/
dSMA-V. D, Full pedigree of family 5. Note the autosomal dominant mode of inheritance and the presence of the G526R mutation in both
individuals with dSMA-V (DNA from other family members was unavailable).
the effect of these mutations on the thermodynamic sta-
bility of GARS cannot be applied. As a rule, a minimum
of 40% sequence identity is required for the results
to be biologically meaningful (A. Baxevanis, personal
communication).
The mechanism by which mutations in such a ubiqui-
tously expressed gene lead to such a highly specific phe-
notype (i.e., peripheral neuropathy/neuronopathy) re-
quires additional investigation. There are two possibil-
ities, in the likely event that the molecular pathology is
due to decreased enzyme activity. First, the phenotype
may arise owing to a general defect in translation effi-
ciency, since every protein-bearing glycine would be af-
fected. In the environment of a typical cell, this defect
may not give rise to a detectable phenotype. However,
cells bearing long axons may be more prone to ensuing
pathology owing to a reduction of protein products
reaching axon termini. Second, there may be a specific
need for more glycine-rich proteins in neurons affected
in CMT2D and dSMA-V. Also intriguing is the fact that
the pathologic mechanism must account for the more
prominent phenotype in specific muscle groups of the
hand. In addition to studies designed to resolve these
issues, it will be of interest to perform GARS mutation
screening in: (1) a broader group of patients with CMT2
and dSMA to assess the frequency of mutations in these
disorders; and (2) patients with neuropathology affect-
ing the thenar eminence in a predominant fashion, for
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example, as seen in carpal tunnel syndrome (Sternbach
1999).
These findings represent the first example of a defect
in an aminoacyl tRNA synthetase being directly asso-
ciated with a human genetic disease. It is interesting that
two mutant forms of the superoxide dismutase 1 gene
(SOD1 [MIM 147450]), the gene implicated in the neu-
rodegenerative disease amyotrophic lateral sclerosis 1
(ALS1 [MIM 105400]), have been shown to interact
directly with lysyl tRNA synthetase (KARS) (Kunst et
al. 1997). Since these interactions are not observed with
wild-type SOD1, this raises the possibility that KARS
inhibition may be involved in the pathology of ALS1.
Thus, the genes for all aminoacyl tRNA synthetases
should be considered relevant candidates for inherited
neuropathies and motor neuron diseases.
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ber AC091755], cat [Felis catus, accession number
AC092009], dog [Canis familiaris, accession numbers
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number AAH21747.1], chicken [Gallus gallus, accession
number AC092081], frog [Xenopus laevis, accession num-
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lotl [Ambystoma mexicanum, accession number BI818038],
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[Takifugu rubripes, accession number AC098806], silkworm
[Bombyx mori, accession number Q04451], fruit fly [Dro-
sophila melanogaster, accession number AAF49668.1], mos-
quito [Anopheles gambiae, accession number EAA10181.1],
roundworm [Caenorhabditis elegans, accession number
NP_498093.1], fission yeast [Schizosaccharomyces pombe,
accession number NP_593935.1], and baker’s yeast [Sac-
charomyces cerevisiae, accession number NP_009679.1])
NCBI Conserved Domain Database, http://www.ncbi.nlm.nih
.gov/entrez/query.fcgi?dbpcdd
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for CMT2D, GARS, SOD1, and
ALS1)
UCSC Genome Browser, http://genome.ucsc.edu (for human
genome)
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